genomics
People and fronts concerned with cancer genomics. 21 records carry it: 20 people, 1 front.
Related tags
21 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Aleix Prat Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI · Hospital Clínic de Barcelona / IDIBAPS Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy. | HER2-positive breast cancer, HR-positive / HER2-negative breast cancer | none | breast, de-escalation | ||
Benjamin Kile Executive Director · Garvan Institute of Medical Research / Kinghorn Cancer Centre Blood cell molecular biologist who has led Sydney's Garvan Institute of Medical Research since 2023, sharpening its focus on genomics, immunology and cancer. | none | none | leadership, clinician-scientist, haematology | ||
Carlos Caldas Professor of Cancer Medicine, University of Cambridge; Senior Group Leader, CRUK Cambridge Institute · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Led METABRIC, which used 2,000 tumours to define ten genomic subtypes of breast cancer and their long-term outcomes. | HR-positive / HER2-negative breast cancer, Triple-negative breast cancer, HER2-positive breast cancer | none | breast, classification | ||
Catherine J. Wu Chief, Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute; Professor, Harvard Medical School · Dana-Farber Brigham Cancer Center Led the first personalised neoantigen peptide vaccine trial in melanoma and mapped how CLL evolves under treatment. | Melanoma, Chronic lymphocytic leukaemia, Glioma & glioblastoma | none | vaccine, neoantigen | ||
Charles M. Perou Professor of Genetics and Pathology, UNC Lineberger Comprehensive Cancer Center · UNC Lineberger Comprehensive Cancer Center Defined the molecular subtypes of breast cancer (luminal, HER2-enriched, basal-like) that clinicians now use every day. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | breast, classification | ||
Christina Curtis Professor of Medicine, Genetics and Biomedical Data Science, Stanford University · Stanford Health Care / Stanford Cancer Institute Showed that colorectal cancers grow as a 'Big Bang' and that metastasis can be seeded years before diagnosis. | Colorectal cancer, HR-positive / HER2-negative breast cancer | none | tumour-evolution, computational | ||
Diagnostics & Biomarkers Tests on tissue and blood that say what kind of cancer it is, what is driving it, and which drugs might work. | none | none | liquid-biopsy, pathology | ||
Douglas A. Levine Director of Gynecologic Oncology, NYU Langone Perlmutter Cancer Center · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes. | Endometrial cancer, Ovarian cancer | none | endometrial, surgery | ||
Ewan Birney Director of EMBL-EBI · EMBL's European Bioinformatics Institute Computational biologist who directs EMBL-EBI, home of the open genomic and cancer data resources used worldwide. | none | none | leadership, bioinformatics | ||
John M. Maris Giulio D'Angio Chair in Neuroblastoma Research, Children's Hospital of Philadelphia · Children's Hospital of Philadelphia Neuroblastoma geneticist whose lab found the ALK mutations and immunotherapy targets now in paediatric trials. | Neuroblastoma | none | paediatric, neuroblastoma | ||
Ludmil B. Alexandrov Professor of Cellular and Molecular Medicine and Bioengineering, UC San Diego · UC San Diego Moores Cancer Center Created the mathematical framework for extracting mutational signatures from cancer genomes and the COSMIC signature catalogue. | none | none | mutational-signatures, computational | ||
Matthew Hurles Director of the Wellcome Sanger Institute and Senior Group Leader · Wellcome Sanger Institute Human geneticist who directs the Wellcome Sanger Institute, a world centre for cancer genome research. | none | none | leadership, clinician-scientist | ||
Michael D. Taylor Professor of Pediatrics and Neurosurgery, Baylor College of Medicine and Texas Children's Hospital · Texas Children's Cancer and Hematology Center Neurosurgeon-scientist who defined the four molecular subgroups of medulloblastoma that now guide therapy. | Medulloblastoma | none | paediatric, medulloblastoma | ||
Michael F. Berger Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Built MSK-IMPACT, the tumour sequencing test used on more than 100,000 patients and the first FDA-authorised hospital panel. | none | none | precision-oncology, diagnostics | ||
Nikhil C. Munshi Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval. | Multiple myeloma | none | myeloma, car-t | ||
Nikolaus Rajewsky Group Leader, Systems Biology of Gene Regulatory Elements; Scientific Director, Berlin Institute for Medical Systems Biology (MDC-BIMSB) · Max Delbrück Center for Molecular Medicine Systems biologist at the MDC known for microRNA and circular RNA discoveries and for single-cell and spatial genomics applied to cancer. | Triple-negative breast cancer, Non-small-cell lung cancer, Neuroblastoma | none | clinician-scientist, systems biology, breast cancer | ||
Nitzan Rosenfeld Professor of Cancer Genomics, Barts Cancer Institute; former Senior Group Leader, CRUK Cambridge Institute · Barts Cancer Institute / Barts Health NHS Trust Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata. | none | none | ctdna, liquid-biopsy | ||
Serena Nik-Zainal Professor of Genomic Medicine and Bioinformatics, University of Cambridge; Honorary Consultant in Clinical Genetics · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Deciphered the mutational signatures written in cancer genomes and turned them into clinical tests like HRDetect. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer | none | mutational-signatures, uk | ||
Silvana Konermann Executive Director and Core Investigator, Arc Institute · Arc Institute Neuroscientist and co-founder who runs the Arc Institute, an independent research institute in the San Francisco Bay Area built to tackle complex diseases. | none | none | leadership, clinician-scientist, research-institute | ||
Stephen Scherer Chief of Research · The Hospital for Sick Children (SickKids) Genome scientist who heads research at SickKids and co-discovered genome-wide copy number variation in humans. | none | none | leadership, clinician-scientist | ||
Steven P. Treon Director, Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug. | Waldenström macroglobulinaemia | none | lymphoma, waldenstrom |
